AU2022294552A1 - Therapeutic method for cat with chronic kidney disease - Google Patents

Therapeutic method for cat with chronic kidney disease Download PDF

Info

Publication number
AU2022294552A1
AU2022294552A1 AU2022294552A AU2022294552A AU2022294552A1 AU 2022294552 A1 AU2022294552 A1 AU 2022294552A1 AU 2022294552 A AU2022294552 A AU 2022294552A AU 2022294552 A AU2022294552 A AU 2022294552A AU 2022294552 A1 AU2022294552 A1 AU 2022294552A1
Authority
AU
Australia
Prior art keywords
bps
group
therapy group
therapy
stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022294552A
Other languages
English (en)
Inventor
Hajimu Kurumatani
Takumi Matsuura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of AU2022294552A1 publication Critical patent/AU2022294552A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022294552A 2021-06-16 2022-06-15 Therapeutic method for cat with chronic kidney disease Pending AU2022294552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021100475 2021-06-16
JP2021-100475 2021-06-16
PCT/JP2022/023876 WO2022265031A1 (ja) 2021-06-16 2022-06-15 慢性腎臓病のネコの治療方法

Publications (1)

Publication Number Publication Date
AU2022294552A1 true AU2022294552A1 (en) 2023-11-02

Family

ID=84527566

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022294552A Pending AU2022294552A1 (en) 2021-06-16 2022-06-15 Therapeutic method for cat with chronic kidney disease

Country Status (11)

Country Link
US (1) US12097177B2 (https=)
EP (1) EP4356908B1 (https=)
JP (1) JP7318818B2 (https=)
KR (1) KR20240021749A (https=)
CN (1) CN117396197A (https=)
AU (1) AU2022294552A1 (https=)
BR (1) BR112023023965A2 (https=)
CA (1) CA3217697A1 (https=)
ES (1) ES3054744T3 (https=)
MX (1) MX2023013545A (https=)
WO (1) WO2022265031A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501556A (ja) * 2021-12-27 2025-01-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 慢性腎臓病を診断及び治療するための組成物及び方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
JPH075582B2 (ja) 1986-01-24 1995-01-25 東レ株式会社 2,5,6,7−テトラノル−4,8−インタ−m−フエニレンPGI▲下2▼誘導体
JPH0662599B2 (ja) 1987-10-16 1994-08-17 東レ株式会社 2,5,6,7―テトラノル―4,8―インタ―m―フェニレンPGI2誘導体ならびにその製造法および用途
CA2012081C (en) 1989-03-14 2000-08-29 Shigeki Itou 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives
WO1998041210A1 (en) 1997-03-14 1998-09-24 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
ES2272914T3 (es) 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
CN101217960B (zh) 2005-07-08 2010-12-15 东丽株式会社 用于改善尿毒症的治疗药和处置方法
JPWO2016031949A1 (ja) 2014-08-28 2017-06-22 東レ株式会社 慢性腎不全の治療薬
CA3164676A1 (en) 2019-12-23 2021-07-01 Toray Industries, Inc. Drug for preventing dialysis shift or renal death

Also Published As

Publication number Publication date
MX2023013545A (es) 2023-11-29
EP4356908A4 (en) 2024-10-23
US12097177B2 (en) 2024-09-24
WO2022265031A1 (ja) 2022-12-22
EP4356908A1 (en) 2024-04-24
CA3217697A1 (en) 2022-12-22
JP7318818B2 (ja) 2023-08-01
CN117396197A (zh) 2024-01-12
JPWO2022265031A1 (https=) 2022-12-22
US20240207218A1 (en) 2024-06-27
BR112023023965A2 (pt) 2024-01-30
EP4356908C0 (en) 2025-10-22
ES3054744T3 (en) 2026-02-05
KR20240021749A (ko) 2024-02-19
EP4356908B1 (en) 2025-10-22
TW202317089A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
RU2493844C2 (ru) Фармацевтические композиции двойного действия на основе надмолекулярных структур антагониста/блокатора рецепторов ангиотензина (arb) и ингибитора нейтральной эндопептидазы (nep)
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンii受容体拮抗薬
EP4356908B1 (en) Method for treating feline with chronic kidney disease
RU2576511C2 (ru) Пероральная терапия недостаточности витамина в12
Jepson et al. Management of chronic kidney disease
KR101848122B1 (ko) 환자 부분모집단에서의 통풍 치료 방법
TWI867128B (zh) 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途
JP5018478B2 (ja) 尿毒症改善のための治療剤および処置方法
AU2019384130A1 (en) Use of higher doses of modified release huperzine formulations
EP1905450A1 (en) Pharmaceutical composition containing ppar gamma agonist
US10639292B2 (en) Method of treating hyperglycemia
RU2778313C2 (ru) Лекарственная композиция, включающая ингибитор sglt-2 и блокатор рецептора ангиотензина
RU2706706C1 (ru) Пероральная осмотическая фармацевтическая композиция вилдаглиптина
KR20240152291A (ko) 중탄산나트륨을 포함하는 운동수행능력 개선용 또는 위장관 장해 개선용 장용성 제제
WO2013050339A1 (en) Pharmaceutical compositions of antihypertensives
CA3131445A1 (en) Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor
HK40031634A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ THERAPEUTIC METHOD FOR CAT WITH CHRONIC KIDNEY DISEASE